Abstract:Objective To elucidate the important role and molecular mechanism of AT1R/miR-26a pathway in hypertensive vascular remodeling. Methods ① Eight-week-old male spontaneously hypertensive rats (SHRs) were randomly divided into losartan group [gavage with losartan 20 mg/(kg·d) for 8 weeks], prazosin group [gavage with prazosin 5 mg/(kg·d) for 8 weeks], SHR control group [gavage with pure water 10 mL/(kg·d) for 8 weeks], with 8 animals in each groups. Six eight-week-old male WKY rats served as normal control group [gavage with pure water 10 mL/(kg·d) for 8 weeks]. All rats in each group were measured for systolic blood pressure (SBP) through tail artery in 3 to 5 d before and during the intervention period until the end of treatment. ② After the rats were anesthetized, the thoracic aorta were harvested for detecting the expression level of miR-26a by real-time quantitative polymerase chain reaction (qPCR). ③ The thoracic aorta was embedded in paraffin, and sectioned for HE and Masson staining, α-actin and PCNA immunohistochemistry. ④ The expression of AT1R, TGFβ1, p-smad3 and CTGF in the thoracic aorta were detected by Western blotting. ⑤ The rat thoracic aortic smooth muscle cells (VSMCs) at 3 to 9 passages were divided into AngⅡ treatment group (VSMCs+AngⅡ, AngⅡ10-7 mol/L, treated for 24 h), and control group (VSMC+Ctrl). qPCR was used to detect the expression level of miR-26a, and the expression of smad3 and p-smad3 was observed by Western blotting. Results ① At the end of treatment received, SBP was significantly lower in the losartan and prazosin groups than the SHR control group, but all of them were obviously higher than that of normal control group (P < 0.05). There was no significant difference in SBP between the losartan and prazosin groups (P>0.05). ②The expression of miR-26a in the thoracic aorta was notably higher in the losartan and prazosin groups than the SHR control group, but statistically lower than the normal control group (P < 0.05), and that of the losartan group was higher than that of the prazosin group (P < 0.05). ③ Media thickness/lumen diameter (MT/LD), collagen volume fraction (CVF), and smooth muscle cell proliferation index in the losartan and prazosin groups were remarkably lower than those in the SHR control group (P < 0.05), and those in the losartan group were lower than those of the prazosin group. The normal control group had no obvious thickening of the vascular wall, with well-arranged smooth muscle cells, and regular morphology of the nucleus, and no significant collagen fiber deposition. ④The expression levels of AT1R, p-smad3, TGFβ1 and CTGF in the thoracic aorta were significantly lower in the losartan and prazosin groups than the SHR control group (P < 0.05). Although those in the losartan group were lower than those of the prazosin group (P < 0.05), the levels in the both group were higher than those of normal control group (P < 0.05). ⑤The expression of miR-26a was significantly lower, and that of p-smad3 was higher in VSMC+AngⅡ group when compared with VSMC+Ctrl group (P < 0.05). Conclusion miR-26a prevents blood pressure from rising and has a protective effect in the process of hypertensive vascular remodeling. Blocking AT1 receptor may improve the remodeling by up-regulating miR-26a.

Role of miR-145 expression in arterial intimal hyperplasia of hypertension in rats

Abstract 394: Chronic Knockdown of the NTS AT1R Increases Circulating Inflammatory-Endothelial Progenitor Cells Ratio and Exacerbates Hypertension in the SHR

MiR-155 Acts As an Inhibitory Factor in Atherosclerosis-Associated Arterial Pathogenesis by Down-Regulating NoxA1 Related Signaling Pathway in ApoE-/- Mouse.

The Regulation of MiR-143/145 on Akt Signaling during VSMC Phenotype Switching in Exercise-induced Hypertensive Arteries

Regulation Mechanism of AT1R/miR-26a Pathway in Hypertensive Vascular Remodeling

The effects of VSMCs phenotype switching and miR-143/145 in arteries during hypertension and aging in rats

[Differential expression of microRNAs in the aorta of spontaneously hypertensive rats]

MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls Vascular Neointimal Lesion Formation

The Antagonistic Effects and Mechanisms of Microrna‐26a Action in Hypertensive Vascular Remodelling

Abstract 050: mir-192-5p in the Kidney is Protective Against the Development of Hypertension

O70 INVOLVEMENT OF MICRORNAs-146a-5P, -155-5P, AND -29b-5P IN CARDIAC REMODELLING AND DYSFUNCTION IN SPONTANEOUSLY HYPERTENSIVE RATS

Inhibition Effect of Microrna-124 on Rat Vascular Smooth Muscle Cell Proliferation and Its Molecular Mechanism

Abstract 059: Mir-29 is Required for Normal Endothelium-dependent Vasodilation and Protects Against Hypertension

MiR155-5p Inhibits Cell Migration and Oxidative Stress in Vascular Smooth Muscle Cells of Spontaneously Hypertensive Rats.

MiR155-5p in Adventitial Fibroblasts-Derived Extracellular Vesicles Inhibits Vascular Smooth Muscle Cell Proliferation Via Suppressing Angiotensin-Converting Enzyme Expression

MicroRNA-155 Regulates Angiotensin II Type 1 Receptor Expression and Phenotypic Differentiation in Vascular Adventitial Fibroblasts

Inhibition of miR-135a-5p attenuates vascular smooth muscle cell proliferation and vascular remodeling in hypertensive rats

MiR-3571 modulates the proliferation and migration of vascular smooth muscle cells by targeting claudin 1

Over-expression of microRNA-145 drives alterations in β-adrenergic signaling and attenuates cardiac remodeling in heart failure post myocardial infarction

Abstract 237: the Inhibitory Effect on Vascular Smooth Muscle Cell Hyperplasia in Artificial Atherosclerotic Mouse Model Via Mir-155 Induced NoxA1 Down Regulation

Role of miR-26a/b in AngⅡ-induced hypertensive vascular remodeling